The management of refractory metastatic colorectal cancer (mCRC) remains constrained by a biologically resistant, immune-excluded tumor microenvironment. In this peer-led debate, experts examine how tumor biology shapes outcomes, scrutinize emerging data with attention to tumor classification, and explore how evidence gaps might influence expectations for meaningful progress. 

Introduction

Metastatic colorectal cancer is largely driven by mismatch repair-proficient/microsatellite stable (MSS) tumors, which are characterized by immune exclusion, hypoxia, and a suppressive tumor microenvironment. In refractory disease, this biology reflects an evolutionarily adapted ecosystem that resists therapy, raising the central question of whether current strategies truly reprogram the TME or only transiently modulate it.

Round 1 

Later-line therapies in refractory mCRC consistently produce modest overall survival gains, suggesting some degree of biologic and microenvironmental modulation. However, very low response rates and limited durability of benefit raise questions about whether these agents meaningfully reprogram the tumor microenvironment or simply provide transient disease control.

Round 2 

Targeting angiogenic and RTK-driven pathways may partially normalize tumor vasculature and influence immune and stromal dynamics within the TME. Yet, persistent immune exclusion, biologic heterogeneity within MSS disease, and lack of biomarker-driven stratification suggest that current approaches may not fully overcome the fundamental barriers to effective microenvironmental reprogramming.

Round 3 

Existing treatment frameworks incorporate key genomic subtypes and have demonstrated consistent, incremental survival benefits across trials. Still, emerging evidence indicates that genomic stratification alone may be insufficient, and integrating tumor microenvironment features could be necessary to more precisely define biologic subgroups and guide therapy in refractory mCRC.